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Abstract 
Introduction: For over 50 years, vitamin K antagonists such as warfarin (Aldocumar®) and acenocoumarol (Sin-
trom®) have been the gold standard for reducing the risk of cerebrovascular events. In the last 5 years alternative 
anticoagulants have been evaluated that act directly upon a concrete target within the coagulation cascade, thereby 
affording a more predictable anticoagulant effect. The present study offers an update on the new oral anticoagulants 
and reviews the implications referred to the dental care of patients administered these substances.
Material and methods: An exhaustive PubMed-Medline and Cochrane Library search was made of the main al-
ternatives to conventional oral anticoagulation, covering those studies published in English and Spanish over the 
last 10 years. Specialized textbooks and pharmaceutical catalogs were also consulted. A total of 184 articles were 
identified, of which 76 met the inclusion criteria.
Results: The new oral anticoagulants dabigatran, rivaroxaban and apixaban are safe and effective, and offer a series 
of advantages, including rapid action, no need for constant monitoring, few drug and food interactions, and a broad 
therapeutic margin. These drugs are expensive, however, and some lack a specific antidote, while others must be 
administered twice a day. Regarding the dental treatment of patients receiving these drugs, suspension or modifi-
cation of the background medication is not required when performing invasive dental procedures, except where 
indicated by the prescribing physician.
Conclusions: The new oral anticoagulants do not pose significantly greater risks than conventional oral anticoagu-
lants when providing invasive dental treatment, and their suspension is not strictly required in such situations.
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Introduction
As a result of the aging of the population and the increa-
se in life expectancy, the prevalence of chronic diseases, 
including heart disorders and cerebrovascular events, is 
growing (1). In order to prevent thromboembolic pro-
blems and infarction, these patients often receive anti-
coagulant treatment – the concrete indications of which 
include atrial fibrillation and other heart arrhythmias; 
venous thromboembolism (deep venous thrombosis, 
pulmonary embolism); acute coronary syndrome and 
myocardial infarction; pulmonary hypertension; and 
heart valve disease and valve prostheses (1,2).
In general terms, oral anticoagulants are effective and re-
liable, offering good tolerance, and rapid absorption after 
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hed in English and Spanish over the last 10 years. Spe-
cialized textbooks and pharmaceutical catalogs were 
also consulted. A total of 184 articles were identified, of 
which 76 (68 literature reviews, 4 metaanalyses and sys-
tematic reviews, and 7 clinical trials) met the inclusion 
criteria. It should be noted that the search yielded only 
three studies on the new oral anticoagulants published in 
the dental literature.
Coagulation cascade
The coagulation cascade was first described in the mid-
1960s, based on in vitro experimental data, and compri-
ses a series of steps through the so-called intrinsic and 
extrinsic coagulation pathways. The intrinsic and extrin-
sic pathways activate different coagulation factors and 
converge in a common pathway that leads to the con-
version of factor X to activated factor Xa. The latter is 
a key element in the conversion of prothrombin (factor 
II) into thrombin, which in turn converts fibrinogen (fac-
tor I) into fibrin (1,11). However, it was soon seen that 
the two pathways do not operate independently of each 
other, and that the above described model is unable to 
explain the physiopathological processes occurring in 
the context of vascular damage (12).
More recent studies demonstrated the importance of the 
cellular component in the coagulation process. Accor-
ding to the current model, coagulation comprises three 
inter-related phases. Initiation phase: this phase is me-
diated by the tissue factor (TF) producing cells. TF is 
a protein found in the membrane of different cells such 
as fibroblasts and monocytes, and gives rise to the ge-
neration of factors Xa and IXa, and to small amounts 
of thrombin that suffice to start the coagulation process. 
Amplification phase: in this phase the platelets are acti-
vated by the generated thrombin, and accumulate fac-
tors and cofactors at surface level, thereby facilitating 
the different enzymatic reactions. Lastly, in the propa-
gation phase, proteases combine with the cofactors at 
platelet surface level, facilitating the production of large 
amounts of thrombin that in turn lead to the formation of 
fibrin and its polymerization to form a stable blood clot 
(Fig. 1) (12).
oral administration, with peak plasma concentrations be-
ing reached after one hour (3,4). In the United Kingdom, 
it has been estimated that about 300,000 people receive 
treatment with oral anticoagulants – the proportional 
number in Spain being approximately 250,000 patients. 
For decades, the drugs used in oral anticoagulation the-
rapy have been the vitamin K antagonists (VKAs) [ace-
nocoumarol (Sintrom®) and warfarin (Aldocumar®)], 
and in patients with special risks or contraindications to 
VKAs, antiplatelet medication has been used as an alter-
native (5). However, these anticoagulants may give rise 
to adverse effects and interactions with different drugs 
and foods. Furthermore, although the antithrombotic 
effects manifest after 48-72 hours, a decrease in coagu-
lation factors is only observed after 5 days of therapy 
(6). The clinical management of these drug substances is 
therefore complicated by the need for close monitoring 
of their activity. These and other factors have limited the 
use of such medicines in routine clinical practice, and 
there has always been a need for new oral anticoagulant 
drugs offering easier handling characteristics, a better 
safety profile, and fewer drug interactions (7).
In this context, Haremberg et al. in the year 2008 (8) 
defined the ideal anticoagulant as a drug offering rapid 
onset of action and a short half-life (easy handling per-
formance in the event of bleeding, without the need to 
add other anticoagulants); predictable pharmacokinetics 
(easier dosing); a predictable anticoagulant effect (fixed 
dose, without the need for monitoring); administration 
via the oral route (thereby facilitating the definition of 
new indications); metabolism not mediated by isoenzy-
me CYP2C9 or VCOR1 (i.e., without drug or food inte-
ractions); availability of an antidote (safety in the event 
of bleeding); and an adequate cost (thereby facilitating 
clinical development). In addition, the development of 
new anticoagulants should seek to offer a small molecu-
lar weight synthetic drug specifically and directly acting 
upon a single coagulation factor (Xa/IIa), with none of 
the known undesired effects of the current drugs, such 
as the coumarin derivatives (7,9,10). Accordingly, in 
the last 5 years, alternative anticoagulants (dabigatran, 
rivaroxaban and apixaban) have been evaluated that act 
directly upon a concrete target within the coagulation 
cascade, thereby affording a more predictable anticoa-
gulant effect.
The present study offers an update on the new oral anti-
coagulants and reviews the implications referred to the 
dental care of patients administered these substances.
Material and methods
An exhaustive PubMed-Medline and Cochrane Library 
search was made of the main alternatives to conven-
tional oral anticoagulation. The key words used were 
“dabigatran”, “rivaroxaban” and “apixaban”, with the 
boolean operator «AND». We included studies publis-
Fig. 1. Classical blood coagulation cascade.
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peak plasma concentrations are reached 1.5-2 hours af-
ter administration. The plasma half-life is 5-9 hours in 
young individuals and 12-33 hours in patients > 75 years 
of age (10,23). The drug is eliminated in urine and bile 
(20). Rivaroxaban shows few interactions with com-
monly used drugs such as aspirin, clopidogrel, digoxin 
or naproxen (1). There have been reports of dyspepsia 
following administration of the drug – this being its most 
frequent non-hematological adverse effect. In the same 
way as the rest of the direct action oral anticoagulants, 
rivaroxaban has no specific antidote (10). However, 
although protamine sulfate is not effective, some stu-
dies suggest that recombinant factor VIIa (Novo Siete®) 
or active concentrated prothrombin complex can revert 
the anticoagulant effect (24). No monitoring is required 
with the use of rivaroxaban.
- Apixaban (Eliquis®)
Apixaban is a potent and reversible factor Xa inhibitor 
with the same therapeutic indications as the above des-
cribed drugs (11,21). Its oral bioavailability is close to 
60%, and the peak plasma concentrations are reached 
1-3 hours after administration, with an elimination half-
life of about 12 hours (11). The drug is fundamentally 
excreted in bile (16). In the same way as dabigatran, 
apixaban is administered twice a day and has no confir-
med specific antidote – though in extreme cases we can 
use rFVIIa, rFXa and activated prothrombin complexes. 
However, in situations of normal bleeding, it suffices 
to postpone a dose or suspend the medication, though 
further studies are needed in this respect (13,25-27). 
Combined administration with potent P-glycoprotein 
and CYP3A4 inhibitors is contraindicated (11). Apixa-
ban is the most recently marketed direct anticoagulant 
(January 2013) (1). 
Table 1 describes the main differences between the vi-
tamin K antagonists (VKAs) and the new oral anticoa-
gulants.
Advantages and inconveniences: new anticoa-
gulants versus vitamin K antagonists
The new direct oral anticoagulants appear to offer a se-
ries of advantages with respect to the classical vitamin K 
antagonists (VKAs) (Table 2). VKAs are slow in acting, 
and patients requiring immediate anticoagulation there-
fore need bridging therapy with a rapid acting agent such 
as heparin. VKAs also present numerous food and drug 
interactions, making it necessary to adopt measures of 
caution referred to diet and especially to changes in con-
comitant medication. Likewise, the classical drugs have 
a narrow therapeutic margin or window, which implies 
an unpredictable anticoagulant effect, with the need for 
regular coagulation controls and dose adjustments in 
order to keep the international normalized ratio (INR) 
within normal limits (16, 28).
The main difference between the two groups of drugs is 
Activity of the new oral anticoagulants
At present, the “new” oral anticoagulants, offering im-
proved possibilities for clinical use, can be classified 
as direct thrombin inhibitors or oral activated factor X 
inhibitors (4,7,9). The anticoagulants belonging to the 
first group are competitive thrombin (factor IIa) inhibi-
tors that avoid the formation of fibrin from fibrinogen, 
independently of the presence of antithrombin, and can 
inactivate both the free (soluble) form of thrombin and 
thrombin bound to fibrin. This group of drugs includes 
ximelagatran and dabigatran (13). The anticoagulants 
belonging to the second group in turn bind to the active 
site of factor Xa in both its soluble form and bound to 
the prothrombinase complex, thereby blocking its inte-
raction with thrombin. A number of drugs are under stu-
dy in this group, though rivaroxaban and apixaban are 
the molecules in the most advanced stages of develop-
ment (5,7,9,14).
- Dabigatran etexilate (Pradaxa®)
Dabigatran etexilate is a direct thrombin inhibitor that 
prevents the conversion of fibrinogen to fibrin (10). Its 
main indication is in programmed (elective) total hip or 
knee replacement surgery. The drug is also indicated in 
the prevention of stroke and systemic embolic disorders 
in adults with non-valvular atrial fibrillation (10,15). It 
is administered twice a day, and its bioavailability af-
ter oral dosing is 6-7%. Dabigatran etexilate is very fast 
acting and reaches peak plasma concentrations between 
1-6 hours after administration, with a half-life of 14-17 
hours. Most of the drug is eliminated through the kid-
neys (80%), and 20% is excreted in bile. Routine moni-
toring is not required (10,15,16). No specific antidote to 
the effects of dabigatran etexilate has been developed to 
date (14,16-18). Interactions have been observed with 
rifampicin, amiodarone, and P-glycoprotein-P inducers / 
inhibitors (10). The most frequent adverse effects (15%) 
are symptoms of gastritis, including dyspepsia, abdomi-
nal pain, and epigastric discomfort (19).
- Rivaroxaban (Xarelto®)
Rivaroxaban is an oxazolidinone derivative that exerts 
a direct inhibitory effect upon factor Xa (20), thereby 
blocking the transformation of prothrombin into throm-
bin, and thus ultimately inhibiting blood clot formation 
(16). It is indicated in the prevention of venous throm-
boembolism in adults subjected to elective hip or knee 
replacement surgery, and in the treatment of deep venous 
thrombosis (DVT) and pulmonary embolism following 
DVT in adult patients. The drug is also indicated in the 
prevention of stroke and systemic embolic disorders in 
adults with non-valvular atrial fibrillation who present 
one or more risk factors (congestive heart failure, hy-
pertension, age ≥ 75 years, diabetes mellitus, previous 
stroke or transient ischemic attack episodes) (10,20,21). 
Rivaroxaban shows high bioavailability following oral 
administration, and a rapid onset of action (22). The 
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their mechanism of action. In effect, while the classical 
drugs block d-carboxylation of the vitamin K-dependent 
coagulation factors (II, VII, IX, X), the new anticoagu-
lants inhibit the coagulation factors directly, thereby en-
suring a safer and more predictable response (1,6,7,18). 
Another important difference is that the new anticoagu-
lants do not require routine monitoring (18). As regards 
cost-effectiveness, although the long-term repercussions 
are not clear (14), a RE-LY study in Navarra (Spain) 
conducted in 2011 reported that obviation of the need 
to control INR would save millions of euros in public 
spending over the long term (29). However, knowing the 
Table 1. Principal characteristics of the vitamin K antagonists and new oral anticoagulants.
Table 2. Advantages and inconveniences of the vitamin K antagonists and new oral anticoagulants.
ADVANTAGES INCONVENIENCES
VKAs:
Acenocoumarol, warfarin
- Antidote: vitamin K
- Many years of established experience
- Less expensive
- Unpredictable response
- Narrow therapeutic margin (INR 2-3)
- Many interactions with drugs and foods
- Increased bleeding risk
New OACs:
Dabigatran, rivaroxaban, apixaban
- Safe and effective: few interactions
- Wide therapeutic margin
- No monitoring required
- Short half-life
- Direct action targeted to a single co-
agulation factor
- Two daily doses, risk of forgotten doses and alteration of 
treatment regimen
- No antidote
- Recently marketed. Caution required
- Short half-life
- No studies in certain populations: obese subjects > 80 kg, low 
weight patients, pediatric patients, pregnant women
- Contraindicated in severe renal failure
- More expensive
VKA: vitamin K antagonist; OAC: oral anticoagulant
ACENOCOUMAROL WARFARIN APIXABAN DABIGATRAN RIVAROXABAN
Daily doses 1 1 2 2 1
Dosage 1 mg, 4 mg 1 mg, 3 mg, 5 mg, 
10 mg
5 mg 110 mg, 150 mg 20 mg
Mechanism of 
action
VKA
× Coagulation F: II, VII, 
IX, X
VKA
× Coagulation F: II, 
VII, IX, X and pro-
teins C and S
Direct Xa inhibitor Free and blood clot-
bound thrombin (fac-
tor IIa) inhibitor
Direct Xa inhibitor
Monitoring Yes Yes No No No
Bioavailability 60% 100% 50% 6-7,2% 80%
Peak plasma con-
centration
2-3 days 2-3 days 3-4 hours 1.5 hours 3 hours
Half-life 2 days 2-5 days 10-14 hours 14-17 hours 4-9 hours
Indications FDA Venous thrombosis and 
pulmonary embolism. 
Thromboembolic compli-
cations associated to atrial 
fibrillation and/or heart 
valve replacement
Venous thrombosis 
and pulmonary em-
bolism. Thromboem-
bolic complications 
associated to atrial 
fibrillation and/or 
heart valve replace-
ment
Prevention of 
thromboembolic 
events in patients 
subjected to elec-
tive knee replace-
ment surgery
Prevention of cerebro-
vascular events and 
systemic embolism in 
non-valvular atrial fi-
brillation
Prevention of venous 
thromboembolism. Hip 
and knee replacement 
surgery. Prevention of 
cerebrovascular events 
and systemic embolism in 
non-valvular atrial fibril-
lation
Interactions Salicylates, NSAIDs, tet-
racycline, ciprofloxacin, 
miconazole and metron-
idazole
Salicylates, NSAIDs, 
tetracycline, cipro-
floxacin, miconazole 
and metronidazole
CYP3A4 inhibi-
tors. CYP3A4/ 
P-glycoprotein in-
hibitors / inducers 
Rifampicin, amio-
darone, P-GP inhibi-
tors / inducers
CYP3A4 inhibitors. CY-
P3A4/ P-glycoprotein in-
hibitors / inducers 
Metabolism Hepatic Hepatic Hepatic 55%, renal 
25%
Renal 80%, hepatic 
20% 
Renal
Current status Over 50 years on the market Marketed in Janu-
ary 2013
Marketed in over 70 countries since 2010
Recommended drug 
detection tests 
INR INR PT; anti-Xa test-
ing calibrated for 
apixaban
aPTT, thrombin time, 
diluted thrombin time; 
ecarin clotting time
PT; anti-Xa testing cali-
brated for rivaroxaban
VKA: vitamin K antagonist; F: factor; FDA: United States Food and Drug Administration; NSAID: nonsteroidal antiinflammatory drug; PT: 
pro- thrombin time; aPTT: activated partial thromboplastin time
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level of anticoagulation may prove necessary in many 
situations, including emergencies, the evaluation of 
treatment compliance, dose confirmation, and for reas-
suring the patient. In this context, sensitive tests have 
been developed that can give us an idea of the anticoa-
gulation status of the patient (Table 1) (11).
Despite the abovementioned advantages, the clinical ex-
perience gained with the new oral anticoagulants is still 
limited, and there are also potential inconveniences such 
as the lack of a direct antidote or of studies conducted 
in specific patient population, e.g., obese individuals, 
pregnant women, pediatric or low-weight patients, etc. 
(18,20,30,31). The fact that the new drugs have a rela-
tively short half-life compared with the VKAs is an ad-
vantage when it comes to suspending anticoagulation in 
the context of programmed surgery, though it is also an 
inconvenience when patients forget to take a dose, sin-
ce such omission leaves them unprotected until the next 
dose is taken (14,31). 
Considerations in dental care
Our review of the literature only yielded three studies 
(reviews) on the new oral anticoagulants in the dental 
care setting (1,10,15). A summarized account of the con-
siderations in dental care among patients receiving the 
new oral anticoagulants is provided below.
There has been controversy for years regarding the sus-
pension or alternation of anticoagulant therapy when 
planning invasive dental treatments. It is well known that 
there is a risk of embolism after suspending antithrom-
botic medication. For this reason, physicians tend to be 
conservative and avoid the suspension of antithrombotic 
medication (particularly with VKAs), provided there is 
no clear contraindication to suspension (6,22,26,32-34). 
Regarding the new direct anticoagulants, the limited 
randomized clinical trials conducted to date do not allow 
us to establish a management protocol. Nevertheless, the 
results based on evidence corresponding to the classi-
cal anticoagulants, and the existing reviews on the new 
drugs, allow us to establish a series of guidelines. 
Two recommendations can be established, depending on 
the bleeding risk of the planned dental treatment:
- Minor bleeding risk (simple extractions < 3, sur-
gery lasting less than 45 minutes) (35): Suspension of 
the direct acting anticoagulant does not seem necessary 
in these cases. Hemostasis is to be facilitated, with local 
measures designed to help healing and minimize the risk 
of post-extraction bleeding (10,15,35).
- Major bleeding risk (multiple extractions > 3, sur-
gery lasting more than 45 minutes, head and neck can-
cer surgery) (35): Operations of this kind can give rise 
to potentially life-threatening bleeding complications. 
Therefore, and depending on the type of operation, the 
existence of renal failure, and the risk of hemostatic 
alterations, the medication should be suspended for a 
number of days before the operation is carried out (33). 
Firriolo et al. (10) and Little (15) recommend suspen-
ding the anticoagulant 24 hours before the operation, 
followed by reintroduction once hemostatic control has 
been achieved. In contrast, other authors such as Spyro-
poulus et al. (35), recommend suspension 2-3 days be-
fore general surgery, followed by reintroduction of the 
medication after 24 hours.
Another factor to be taken into account in the manage-
ment of these patients is renal function. In this sense, 
some authors such as Van Ryn et al. (36) offer recom-
mendations depending on the creatinine clearance va-
lues of the patient (Table 3).
Management must be optimized from preoperative wor-
kup to the postoperative period in all patients subjected 
to antithrombotic treatment. Surgery should be perfor-
med in the morning and at the start of the week in order 
to guarantee enough time to adequately deal with any 
possible complications (6,10,32,37,38). Good soft tissue 
management is essential in this sense, in order to avoid 
excessive traumatism of the surgical zone.
The main complication we can find is the lack of an an-
tidote (30), which may pose a risk in the case of heavy 
bleeding as a result of dental surgery. Nevertheless, the-
re are a number of lines of research, including the use of 
prothrombin complex concentrates (PCCs), which could 
neutralize the effect of rivaroxaban; the administration of 
recombinant factor VIIa; or the use of dialysis for neu-
tralizing the effect of dabigatran. These options must be 
viewed with caution, however, since further studies are 
needed in order to confirm their efficacy (11,31,33,34). 
It is therefore important to use local hemostatic measu-
res to help ensure good bleeding control (32). Supple-
mentary measures have also been recommended, such 
as the use of absorbable hemostatic dressings in the 
form of oxidized cellulose (Surgicel®), collagen spon-
ges (Haemocollagel®), or reabsorbable gelatin sponges 
Table 3. Direct anticoagulant suspension time according to creatinine clearance value.
Renal function
(Creatinine clearance 
ml/min)
Half-life of the drug 
(hours)
Time from last drug dose to surgery
Lesser bleeding risk 
(hours)
High bleeding risk 
(days)
> 80 13 (11-22) 24 2-4 
50-80 15 (12-34) 24 2-4 
30-50 18 (13-23) 48 4 
< 30 27 (22-35) 2-5 days 5 
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(Spongostan®). In order to avoid postoperative bleeding, 
it is advisable to suture the extraction socket and apply 
compressive dressings impregnated with tranexamic 
acid (1).
Conclusions
The introduction of the new direct action oral anticoagu-
lants poses a number of challenges in dental surgery. The 
lack of an antidote in the event of postoperative bleeding 
requires maximum caution when using these drugs. Fur-
ther randomized studies are needed to establish the effi-
cacy and safety of dental treatment in patients receiving 
these new anticoagulants.
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